Zenas BioPharma designates Simon Lowry Chief Medical Officer

KUALA LUMPUR, Sept 8 (Bernama) -- Zenas BioPharma, a global biopharmaceutical company has announced the appointment of Simon Lowry, M.D., as the company’s Chief Medical Officer.

According to a statement, Dr Lowry brings over 20 years of broad clinical expertise in the design and execution of early to late-stage clinical programmes to Zenas, where he will lead the company’s global clinical, medical affairs, and pharmacovigilance functions.

“We are delighted to welcome Dr Lowry to Zenas at this pivotal time for the company as we commence two phase three registration trials for our lead product candidate, obexelimab, in the fourth quarter of this year and initiate first-in-human clinical trials for multiple pipeline programmes,” said Chief Executive Officer at Zenas, Hua Mu, M.D., Ph. D.

“Dr Lowry’s proven leadership, broad clinical development background, and extensive global clinical trial experience will further strengthen our ability to execute on our mission to transform the lives of patients with unmet medical needs by bringing best-in-class immune-based therapies to patients.”

Meanwhile, Dr Lowry said: “The deeply experienced and talented Zenas team has made impressive progress advancing the company’s pipeline in a very short period of time.

“I look forward to leading the ongoing advancement of Zenas’ clinical programmes through commercialisation while further expanding the company’s pipeline of innovative programmes.”

Dr Lowry is a medical doctor with 20 years of experience at large and emerging pharmaceutical and biotechnology companies directing successful development programmes, leading clinical and medical affairs teams, and interacting with regulatory agencies across multiple areas of medicine.

Prior to joining Zenas, he was Chief Medical Officer at Kinevant Science, a clinical-stage biopharmaceutical company focused on treating rare inflammatory and autoimmune diseases.

-- BERNAMA